A lack of consensus guidelines or a belief that current evidence does not support such guidelines might be justified if a clinician expresses a commitment to patient-centered care and shared decision making.
AMA J Ethics. 2018;20(11):E1007-1016. doi:
10.1001/amajethics.2018.1007.
Prevention efforts can marginalize patients by stigmatizing certain behaviors, so distinguishing individual professionals’ preferences about those behaviors is critical.
AMA J Ethics. 2019;21(6):E536-539. doi:
10.1001/amajethics.2019.536.
Legacy patients are so-called because their opioid use behaviors express past, aggressive opioid prescribing by a clinician. Managing their pain and dependence justly is ethically complex.
AMA J Ethics. 2020;22(8):E651-657. doi:
10.1001/amajethics.2020.651.
Marissa Chaet Brykman, JD, Virginia Streusand Goldman, PhD, Nandakumara Sarma, PhD, RPh, Hellen A. Oketch-Rabah, PhD, MSc, Deborah Biswas, JD, and Gabriel I. Giancaspro, PhD
Increase in dietary supplement use in the United States suggests a great need for clinicians to be aware of the range of their quality parameters.
AMA J Ethics. 2022;24(5):E382-389. doi:
10.1001/amajethics.2022.382.
Marissa Chaet Brykman joins Ethics Talk to discuss her article, coauthored with Dr Virginia Streusand Goldman, Dr Nandakumara Sarma, Dr Hellen A. Oketch-Rabah, Deborah Biswas and Dr Gabriel I. Giancaspro: “What Should Clinicians Know About Dietary Supplement Quality?”